Wang, Yunwei <br/><br/>
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.  [electronic resource] 

 -  Journal of gastroenterology and hepatology  Dec 2019 
 - 2090-2095 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1440-1746 
<br/><br/><label>Standard No.: </label>10.1111/jgh.14751  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Colitis, Ulcerative--drug therapy<br/>Colonoscopy<br/>Crohn Disease--drug therapy<br/>Drug Substitution--methods<br/>Female<br/>Gastrointestinal Agents--adverse effects<br/>Humans<br/>Inflammatory Bowel Diseases--drug therapy<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Remission Induction<br/>Retrospective Studies<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Tumor Necrosis Factor Inhibitors--therapeutic use<br/>Young Adult